Cargando…

Chemokine-Like Receptor 1 Deficiency Does Not Affect the Development of Insulin Resistance and Nonalcoholic Fatty Liver Disease in Mice

The adipokine chemerin and its receptor, chemokine-like receptor 1 (Cmklr1), are associated with insulin resistance and nonalcoholic fatty liver disease (NAFLD), which covers a broad spectrum of liver diseases, ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). It is possible that...

Descripción completa

Detalles Bibliográficos
Autores principales: Gruben, Nanda, Aparicio Vergara, Marcela, Kloosterhuis, Niels J., van der Molen, Henk, Stoelwinder, Stefan, Youssef, Sameh, de Bruin, Alain, Delsing, Dianne J., Kuivenhoven, Jan Albert, van de Sluis, Bart, Hofker, Marten H., Koonen, Debby P. Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004559/
https://www.ncbi.nlm.nih.gov/pubmed/24781986
http://dx.doi.org/10.1371/journal.pone.0096345
_version_ 1782313991186415616
author Gruben, Nanda
Aparicio Vergara, Marcela
Kloosterhuis, Niels J.
van der Molen, Henk
Stoelwinder, Stefan
Youssef, Sameh
de Bruin, Alain
Delsing, Dianne J.
Kuivenhoven, Jan Albert
van de Sluis, Bart
Hofker, Marten H.
Koonen, Debby P. Y.
author_facet Gruben, Nanda
Aparicio Vergara, Marcela
Kloosterhuis, Niels J.
van der Molen, Henk
Stoelwinder, Stefan
Youssef, Sameh
de Bruin, Alain
Delsing, Dianne J.
Kuivenhoven, Jan Albert
van de Sluis, Bart
Hofker, Marten H.
Koonen, Debby P. Y.
author_sort Gruben, Nanda
collection PubMed
description The adipokine chemerin and its receptor, chemokine-like receptor 1 (Cmklr1), are associated with insulin resistance and nonalcoholic fatty liver disease (NAFLD), which covers a broad spectrum of liver diseases, ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). It is possible that chemerin and/or Cmklr1 exert their effects on these disorders through inflammation, but so far the data have been controversial. To gain further insight into this matter, we studied the effect of whole-body Cmklr1 deficiency on insulin resistance and NAFLD. In view of the primary role of macrophages in hepatic inflammation, we also transplanted bone marrow from Cmklr1 knock-out (Cmklr1(-/-)) mice and wild type (WT) mice into low-density lipoprotein receptor knock-out (Ldlr(-/-)) mice, a mouse model for NASH. All mice were fed a high fat, high cholesterol diet containing 21% fat from milk butter and 0.2% cholesterol for 12 weeks. Insulin resistance was assessed by an oral glucose tolerance test, an insulin tolerance test, and by measurement of plasma glucose and insulin levels. Liver pathology was determined by measuring hepatic inflammation, fibrosis, lipid accumulation and the NAFLD activity score (NAS). Whole-body Cmklr1 deficiency did not affect body weight gain or food intake. In addition, we observed no differences between WT and Cmklr1(-/-) mice for hepatic inflammatory and fibrotic gene expression, immune cell infiltration, lipid accumulation or NAS. In line with this, we detected no differences in insulin resistance. In concordance with whole-body Cmklr1 deficiency, the absence of Cmklr1 in bone marrow-derived cells in Ldlr(-/-) mice did not affect their insulin resistance or liver pathology. Our results indicate that Cmklr1 is not involved in the pathogenesis of insulin resistance or NAFLD. Thus, we recommend that the associations reported between Cmklr1 and insulin resistance or NAFLD should be interpreted with caution.
format Online
Article
Text
id pubmed-4004559
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-40045592014-05-02 Chemokine-Like Receptor 1 Deficiency Does Not Affect the Development of Insulin Resistance and Nonalcoholic Fatty Liver Disease in Mice Gruben, Nanda Aparicio Vergara, Marcela Kloosterhuis, Niels J. van der Molen, Henk Stoelwinder, Stefan Youssef, Sameh de Bruin, Alain Delsing, Dianne J. Kuivenhoven, Jan Albert van de Sluis, Bart Hofker, Marten H. Koonen, Debby P. Y. PLoS One Research Article The adipokine chemerin and its receptor, chemokine-like receptor 1 (Cmklr1), are associated with insulin resistance and nonalcoholic fatty liver disease (NAFLD), which covers a broad spectrum of liver diseases, ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). It is possible that chemerin and/or Cmklr1 exert their effects on these disorders through inflammation, but so far the data have been controversial. To gain further insight into this matter, we studied the effect of whole-body Cmklr1 deficiency on insulin resistance and NAFLD. In view of the primary role of macrophages in hepatic inflammation, we also transplanted bone marrow from Cmklr1 knock-out (Cmklr1(-/-)) mice and wild type (WT) mice into low-density lipoprotein receptor knock-out (Ldlr(-/-)) mice, a mouse model for NASH. All mice were fed a high fat, high cholesterol diet containing 21% fat from milk butter and 0.2% cholesterol for 12 weeks. Insulin resistance was assessed by an oral glucose tolerance test, an insulin tolerance test, and by measurement of plasma glucose and insulin levels. Liver pathology was determined by measuring hepatic inflammation, fibrosis, lipid accumulation and the NAFLD activity score (NAS). Whole-body Cmklr1 deficiency did not affect body weight gain or food intake. In addition, we observed no differences between WT and Cmklr1(-/-) mice for hepatic inflammatory and fibrotic gene expression, immune cell infiltration, lipid accumulation or NAS. In line with this, we detected no differences in insulin resistance. In concordance with whole-body Cmklr1 deficiency, the absence of Cmklr1 in bone marrow-derived cells in Ldlr(-/-) mice did not affect their insulin resistance or liver pathology. Our results indicate that Cmklr1 is not involved in the pathogenesis of insulin resistance or NAFLD. Thus, we recommend that the associations reported between Cmklr1 and insulin resistance or NAFLD should be interpreted with caution. Public Library of Science 2014-04-29 /pmc/articles/PMC4004559/ /pubmed/24781986 http://dx.doi.org/10.1371/journal.pone.0096345 Text en © 2014 Gruben et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Gruben, Nanda
Aparicio Vergara, Marcela
Kloosterhuis, Niels J.
van der Molen, Henk
Stoelwinder, Stefan
Youssef, Sameh
de Bruin, Alain
Delsing, Dianne J.
Kuivenhoven, Jan Albert
van de Sluis, Bart
Hofker, Marten H.
Koonen, Debby P. Y.
Chemokine-Like Receptor 1 Deficiency Does Not Affect the Development of Insulin Resistance and Nonalcoholic Fatty Liver Disease in Mice
title Chemokine-Like Receptor 1 Deficiency Does Not Affect the Development of Insulin Resistance and Nonalcoholic Fatty Liver Disease in Mice
title_full Chemokine-Like Receptor 1 Deficiency Does Not Affect the Development of Insulin Resistance and Nonalcoholic Fatty Liver Disease in Mice
title_fullStr Chemokine-Like Receptor 1 Deficiency Does Not Affect the Development of Insulin Resistance and Nonalcoholic Fatty Liver Disease in Mice
title_full_unstemmed Chemokine-Like Receptor 1 Deficiency Does Not Affect the Development of Insulin Resistance and Nonalcoholic Fatty Liver Disease in Mice
title_short Chemokine-Like Receptor 1 Deficiency Does Not Affect the Development of Insulin Resistance and Nonalcoholic Fatty Liver Disease in Mice
title_sort chemokine-like receptor 1 deficiency does not affect the development of insulin resistance and nonalcoholic fatty liver disease in mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004559/
https://www.ncbi.nlm.nih.gov/pubmed/24781986
http://dx.doi.org/10.1371/journal.pone.0096345
work_keys_str_mv AT grubennanda chemokinelikereceptor1deficiencydoesnotaffectthedevelopmentofinsulinresistanceandnonalcoholicfattyliverdiseaseinmice
AT apariciovergaramarcela chemokinelikereceptor1deficiencydoesnotaffectthedevelopmentofinsulinresistanceandnonalcoholicfattyliverdiseaseinmice
AT kloosterhuisnielsj chemokinelikereceptor1deficiencydoesnotaffectthedevelopmentofinsulinresistanceandnonalcoholicfattyliverdiseaseinmice
AT vandermolenhenk chemokinelikereceptor1deficiencydoesnotaffectthedevelopmentofinsulinresistanceandnonalcoholicfattyliverdiseaseinmice
AT stoelwinderstefan chemokinelikereceptor1deficiencydoesnotaffectthedevelopmentofinsulinresistanceandnonalcoholicfattyliverdiseaseinmice
AT youssefsameh chemokinelikereceptor1deficiencydoesnotaffectthedevelopmentofinsulinresistanceandnonalcoholicfattyliverdiseaseinmice
AT debruinalain chemokinelikereceptor1deficiencydoesnotaffectthedevelopmentofinsulinresistanceandnonalcoholicfattyliverdiseaseinmice
AT delsingdiannej chemokinelikereceptor1deficiencydoesnotaffectthedevelopmentofinsulinresistanceandnonalcoholicfattyliverdiseaseinmice
AT kuivenhovenjanalbert chemokinelikereceptor1deficiencydoesnotaffectthedevelopmentofinsulinresistanceandnonalcoholicfattyliverdiseaseinmice
AT vandesluisbart chemokinelikereceptor1deficiencydoesnotaffectthedevelopmentofinsulinresistanceandnonalcoholicfattyliverdiseaseinmice
AT hofkermartenh chemokinelikereceptor1deficiencydoesnotaffectthedevelopmentofinsulinresistanceandnonalcoholicfattyliverdiseaseinmice
AT koonendebbypy chemokinelikereceptor1deficiencydoesnotaffectthedevelopmentofinsulinresistanceandnonalcoholicfattyliverdiseaseinmice